| 000 | 01853 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517082520.0 | ||
| 264 | 0 | _c20171127 | |
| 008 | 201711s 0 0 eng d | ||
| 022 | _a1949-2553 | ||
| 024 | 7 |
_a10.18632/oncotarget.7667 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNakayama, Robert | |
| 245 | 0 | 0 |
_aPreclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. _h[electronic resource] |
| 260 |
_bOncotarget _cMar 2016 |
||
| 300 |
_a16581-92 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aBlotting, Western |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDrug Screening Assays, Antitumor _xmethods |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aG1 Phase Cell Cycle Checkpoints _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydrazines _xpharmacology |
| 650 | 0 | 4 |
_aKaryopherins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-kit _xgenetics |
| 650 | 0 | 4 |
_aReceptors, Cytoplasmic and Nuclear _xantagonists & inhibitors |
| 650 | 0 | 4 | _aReverse Transcriptase Polymerase Chain Reaction |
| 650 | 0 | 4 |
_aSarcoma _xdrug therapy |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 |
_aTriazoles _xpharmacology |
| 650 | 0 | 4 |
_aXenograft Model Antitumor Assays _xmethods |
| 650 | 0 | 4 | _aExportin 1 Protein |
| 700 | 1 | _aZhang, Yi-Xiang | |
| 700 | 1 | _aCzaplinski, Jeffrey T | |
| 700 | 1 | _aAnatone, Alex J | |
| 700 | 1 | _aSicinska, Ewa T | |
| 700 | 1 | _aFletcher, Jonathan A | |
| 700 | 1 | _aDemetri, George D | |
| 700 | 1 | _aWagner, Andrew J | |
| 773 | 0 |
_tOncotarget _gvol. 7 _gno. 13 _gp. 16581-92 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.18632/oncotarget.7667 _zAvailable from publisher's website |
| 999 |
_c25773045 _d25773045 |
||